Publications by authors named "Clemence Pleyers"
Cervical cancer (CC) is the fourth most common neoplasia in women worldwide. Although early-stage CC is often curable, 40 to 50% of patients are diagnosed at a locally advanced stage. Metastatic disease accounts for the principal cause of death.
View Article and Find Full Text PDFCervical cancer is the 4th most diagnosed cancer in women. At a locally advanced stage, standard treatment combines chemotherapy, radiotherapy and a brachytherapy boost. Brachytherapy is a radiotherapy modality, often unknown, which allows the delivery of a very targeted high dose because it's given directly in contact with the tumor.
View Article and Find Full Text PDFArticle Synopsis
- * This study compared the diagnostic performance of immunohistochemistry (IHC) to molecular techniques to accurately assess microsatellite instability (MSI) and p53 mutations in endometrial cancer patients.
- * Results showed IHC had a high agreement with the gold standard for MSI status (kappa = 0.74) but only a moderate agreement for p53 status (kappa = 0.59), suggesting they are not interchangeable for p53 evaluations.
Purpose: To develop machine learning models to predict para-aortic lymph node (PALN) involvement in patients with locally advanced cervical cancer (LACC) before chemoradiotherapy (CRT) using F-FDG PET/CT and MRI radiomics combined with clinical parameters.
Methods: We retrospectively collected 178 patients (60% for training and 40% for testing) in 2 centers and 61 patients corresponding to 2 further external testing cohorts with LACC between 2010 to 2022 and who had undergone pretreatment analog or digital F-FDG PET/CT, pelvic MRI and surgical PALN staging. Only primary tumor volumes were delineated.
Purpose: This monocentric study aimed to assess the impact of technical advancement in brachytherapy (BT) on local control (LC) and cancer-specific survival (CSS) in locally advanced cervical cancer (LACC).
Methods: Since 2010, 211 patients with LACC have been treated with 45/50.4 Gy or 60 Gy radiochemotherapy (RTCT) followed by image-guided adaptive brachytherapy (IGABT) at the authors' institution.